Healthcare Industry News: Mesothelioma
News Release - August 2, 2007
Kylin Therapeutics Names Cancer Therapy Leader to Its Board of DirectorsLeading Health Care Professional Becomes Newest Member of Board
WEST LAFAYETTE, Ind.--(HSMN NewsFeed)--Kylin Therapeutics Inc. announces its newest member to serve on its board of directors - a retired Eli Lilly and Co. executive.
Homer L. Pearce, a retired distinguished research fellow and former Lilly vice president of cancer research and clinical investigation, joined the Kylin board of directors.
"Homer Pearce is a recognized leader in the field of cancer drug discovery and development," said Eric Davis, chief executive officer of Kylin. "His experience in health care, strategic planning and decision making will bring much to our board of directors. We are especially excited about his experience with RNA-based therapeutics and the early collaborations he led while at Lilly."
Pearce, of Indianapolis, spent more than 27 years on cancer drug research and discovery at Lilly. He was involved in the development of more than 25 investigational drugs, of which three have resulted in regulatory approvals, including Gemzar® and Alimta®. Pearce was recently named "A Hero of Chemistry" by the American Chemical Society for his role in the discovery and development of the drug Alimta. Alimta is the first drug ever approved for the treatment of malignant pleural Mesothelioma, a cancer caused by exposure to asbestos.
Pearce earned his doctoral degree from Harvard University and his bachelor's degree from Texas A&M University.
About Kylin Therapeutics Inc.
Kylin Therapeutics Inc. (http://www.kylintherapeutics.com) is a cutting-edge biotechnology company that has offices at the Purdue Research Park. The company employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.
Source: Kylin Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.